Eight commercially available immunoassays for amphetamines (DRI | Amphetamines, CEDIA | DAU AmphetaminesSemiquantitative, EMIT r d.a.u. Monoclonal Amphetamine/Methamphetamine, Synchron CX | Systems AMPH, TDx~/TDxFLx | Amphetamine/Methamphetamine II, CEDIA Amphetamines/Ecstasy, COBAS | INTEGRA Amphetamines, and Abuscreen | OnLine HS Amphetamine/MDMA) are evaluated for their effectiveness in serving as the preliminary test methodology for the analysis of 3,4-methylenedioxymethamphetamine/ 3,4-methylenodioxyamphetamine (MDMA/MDA) and methamphetamine/amphetamine (MA/AM). Standard solutions (in urine matrix) of MDMA, MDA, MA, and AM are used to determine these immunoassays' reactivities (or cross-reactivities) toward these compounds of interest. Case specimens containing MDMA/MDA and MA/AM are also used to study the correlations of the apparent immunoassay MDMA (or MA) concentrations and the gas chromatographic--mass spectrometric concentrations of these compounds. Data resulting from this study suggest that CEDIA Amphetamines/Ecstasy can best predict the concentrations of MDMA and MA in case specimens and can also detect the presence of MDMA at low levels, whereas Abuscreen OnLine HS Amphetamine/MDMA can detect both MDMA and MA at low concentrations.
Introduction
Along with heroin, methamphetamine (MA) has long been one of the two most commonly abused drugs in Taiwan. With recent popularity of "club" drugs, especially ecstasy (3,4-9 Author to whom correspondence should be addressed. methylenedioxymethamphetamine, MDMA), among the younger population (1), we are interested in better understanding the performance characteristics and effectiveness of various commercially available imnmunoassays for the preliminary identification of urine specimens that contain MA or MDMA and their metabolites, amphetamine (AM) and 3,4-methylenedioxyamphetamine (MDA), respectively.
There have been several reported studies addressing the performance characteristics of immunoassays for amphetamines. For example, in 1988, Ruangyuttikam and Moody (2) reported low MDMA cross-reactivity of the three immunoassays (Abuscreen RIA, EMIT, and TDx) that adapted MA/AM as the targeted analytes. In 1990, Kunsman et al. (3) reported that MDMA cross-reactivity exhibited by EMIT d.a.u. Monoclonal Amphetamine/Methamphetamine was generally low, while that exhibited by TDx Amphetamine/Methamphetamine was high (118%) at low concentration (150 ng/mL), but unacceptably low (18%) at a higher level (10 IJg/mL). Zhao et al. (4) recently evaluated TDx, EMIT II, CEDIA DAU Amphetamines, and five different Abuscreen OnLine formats and concluded that TDx Amphetamine/Methamphetamine II and Abuscreen OnLine HS Amphetamine/MDMA displayed greater detection sensitivity for MDMA. Very recently, scientists from the manufacturer reported the performance characteristics of Multiplex CEDIA Amphetamines/Ecstasy (5), which incorporates three monoclonal antibodies specific for AM, MA, and MDMA.
This study is characterized by 1. the evaluation of an extended list of reagents under the same settings; 2. the emphasis on the effectiveness in simultaneous detection of MDMA/MDA and MA/AM by these immunoassays; and 3. the correlation of case specimen data derived from these immunoassays and gas chromatographic-mass spectrometric (GC-MS) procedures.
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Materials and Methods
Immunoassay reagents and analyzers
Immunoassays and analyzers used in this study are summarized in Table I. All immunoassay reagents were prepared used according to the instructions provided by respective manufacturers for the specified analyzers used for the analysis. Name abbreviations of these immunoassays as listed in Table I  shall be used for discussion 
Immunoassay
The procedures described in respective reagent package inserts were followed using calibrators provided by respective manufacturers. However, an additional test was performed for CEDIA AmplMDMA reagent, in which MDMA was used as the calibrator (see the Results and Discussion section for further discussion). 
GC-MS procedures
For specimen pretreatrnent, 2-rnL urine aliquots were extracted with ethyl acetate under basic conditions. Heptafluorobutyric anhydride (HFBA) (Aldrich, St. Louis, MO) was used to derivatize the analytes (AM, MA, MDMA, and MDA) and deuterated internal standards (MA-dg, AM-dg, MDMA-ds, and MDA-ds).
GC-MS analysis was performed on an HP 6890 GC interfaced to an HP 5973N MS (Agilent, Paio Alto, CA). A 30-rn x 0.25-rnm (0.25-]Jrn film thickness) HP-5MS capillary column (Agilent, Wilmington, DE) was used for this study. The GC column was operated at an initial temperature of 90~ for 1 min, programmed to 280~ 41.AM at 15~ with a 3-rnin hold at the final temperature. Ions monitored and those adapted for the quantitation of AM, MA, MDMA, and MDA are shown in Table ] I. Fullscan mass spectra of these compounds and their deuterated analogues are shown in Figures 1 and 2 . Confirming the presence of a specific analyte is based on the widely adapted criteria, that is, presence of the monitored ions at the acceptable retention time (within • 2% of that established by the standards) and two independent intensity ratios of the three ions monitored (within • 20% of those established by the standards).
* Except those noted, the concentration ranges tested were 300-1000 ng/mL for MDMA,/MDA/MDEA and 300-2000 ng/mL for d,I-AM/d,I-MA. Typically, higher cross-reactivity values were observed when the drug concentralions were at the lower end (300 ng/mL). N.E.: Not evaluated. * Concentration range tested: 200-300 ng/mL At higher concentrations, responses exceed the analyzer's response range. w Concentration tested: 300 ng/mL. Responses at higher concentrations exceed the analyzer's response range. m Standard MDMA from Ihe same source was used for calibration and cross-reaclivity study.
Results and Discussion
Cross-reactivity studies of MA, AM, MDMA, MDA, and MDEA Reactivity data of MA, AM, MDMA, MDA, MDEA from the irnrnunoassays that were evaluated are summarized in Table [ [I. These values were calculated by dividing the observed immunoassay concentrations by the true concentrations of the standards used for the study and the results are expressed as percentages. Because the calibrators were typically d-enantiomers (d-AM or d-MA) and the prepared solutions used for evaluation were typically racemic mixtures (d,I-AM and d,I-MA), the observed cross-reactivity data were typically not 100%, even when the calibrators and the standards were the same compound at the same concentration.
Data shown in Table III indicate the following performance characteristics: 1. Cross-reactivity data are typically lower when the compounds examined are at the higher concentration (see Figures 3 and 4 4 . Among those designed for the detection of MA/AM, the following immunoassays have _> 50% cross-reactivity toward MDMA and MDA: DRI-Amp, Synchron-CX-Amp, and TDx-Amp. The following two immunoassays have > 50% cross-reactivity toward MDMA, but not MDA: CEDIA-Amp, COBAS-Amp. [Fifty percent cross-reactivity is the proposed minimum acceptable value in the draft guidelines of the National Laboratory Certification Program (7)]. EMIT-Amp has high cross-reactivity toward MDA, but is probably not effective if used for the detection of MDMA at the 500 ng/mL level.
Immunoassay and GC-MS data derived from MDMA/MDA-and MA/AMocontaining urine specimens
Because the use of various commercially available immunoassays for the preliminary test of MA/AM has been well established, the primary emphasis of this study is on charac-"~ 160
:. Performance characteristics of irnmunoassays in the analysis of AIDHA. Shown in Table IV Table IV) , of which data for certain immunoassays are not available (exceeding the upper response limit), are excluded all together to ensure that comparisons are based on plots generated by the identical set of specimens.
The four plots shown in Figure 5 reveal the following performance characteristics:
Correlation of immunoassays and GC-MS data. Results derived from CEDIA-Amp/MDMA (MDMA as calibrator) ( Figure  5D ) and COBAS-Amp ( Figure 5B with GC-MS MDMA concentrations (r 2 = 0.5117 and 0.4143). Apparent MDMA concentrations equivalent to 500 ng/mL MDMA for these two immunoassays are approximately 543 ng/rnL and 475 ng/mL, respectively. This is an indication of limited cross-reactivities of these two immunoassays toward MDMA metabolites, such as MDA, an observation consistent with crossreactivity data shown in Table III .
OnLine-Amp/MDMA ( Figure 5C ) exhibits poor correlation (r ~ = 0.0876) with GC-MS MDMA concentration. Apparent MDMA concentrations equivalent to 500 ng/mL MDMA for this immunoassay is approximately 723 ng/mL. This is most likely due to this reagent's higher response toward MDMA and higher cross-reactivities toward MDA and other MDMA metabolites present in the specimens. This is consistent with the higher cross-reactivity (100-75% for OnLine-Amp/MDMA of this reagent toward MDA shown in Table III .
The performance of TDx-Arnp ( Figure 5A ) falls between the characteristics exhibited by CEDIA-Arnp/MDMA (and COBASAmp) and OnLine-Amp/MDMA.
Detectivitg. CEDIA-Amp/MDMA (d-MA as calibrator) (data not shown) and OnLine-Amp/MDMA ( Figure 5C ) exhibit the highest responses toward MDMA. These assays will detect more specimens containing MDMA and metabolites than the other methods. Table V are GC-MS and immunoassay apparent MA concentration data derived from 32 MA/AM-containing specimens. Only the data derived from the four immunoassays (TDx-Amp, COBAS-Amp, OnLine-Amp/MDMA, CEDIAAmp/MDMA), which show potentially effectiveness for the analysis of MDMA, are evaluated. Specifically, apparent MA concentrations derived from these immunoassays are plotted against the GC-MS MA concentration as shown in Figures  6A-D . Again, the same set of x-and y-axis are used for all plots to facilitate visual comparison. Data derived from eight specimens (footnoted in Table V) , for which data for certain immunoassays are not available or are of dubious nature, are excluded all together to ensure that comparisons are based on plots generated from the identical set of specimens.
Performance characteristics of immunoassays for analyzing
MA. Shown in
The four plots shown in Figure 6 reveal the following perfor- * These data were obtained using MDMA as the calibrator. With the exception of two specimens, responses exceeded instrument measurement limit when using d-MA as the calibrator, t Responses exceed the analyzer's response range. * Data derived from these specimens are not plotted in Figure 5 (see text for reasons), s Data not available.
mance characteristics: 1. Results derived from CEDIA-Amp/ MDMA (d-NA as calibrator) ( Figure 6D ) and TDx-Amp ( Figure  6A) show the best correlations with GC-MS MA con centration (r 2 = 0.2222 and 0.207, respectively). Apparent MA concentrations equivalent to 500 ng/mL MA for these two immunoassays are approximately 1146 ng/mL and 1420 ng/mL, respectively. 2. .~ ~ 420o. OnLine-Amp/MDMA ( Figure 6C ) exhibits the highest response, but shows poorer correlation (r 2 = 0.1616) with GC-MS MA concentration. Apparent MA concentration equivalent to 500 ng/mL MA for this immunoassay is approximately 2582 ng/mL. This is most likely due to this reagent's higher response toward MA and higher cross-reactivities toward AM and other MA metabolites present in the specimens. This is consistent with the high response to MA (355-227%) and high crossreactivity with AM (197-125%) shown in Table  III . Thus, the presence of MA (and its metabolites) can be most effective detected by this reagent. However, because of the poor correlation of the immunoassay and GC--MS data, this reagent will not be very effective in predicting the concentration of MA.
Effectiveness in identifying specimens "positive" for MDMA and MA
Case specimen data shown in Tables IV and V can be used to examine these immunoassays' effectiveness in identifying specimens that are "positive" (above an adapted cutoff) for MDMA/MDA and MA/AM, respectively. "Falsenegative" and "false-positive" rates will obviously vary when different "cutoffs" are applied to immunoassay data (i.e., when a lower immunoassay cutoff is adapted, the false-positive rate will increase, and the corresponding falsenegative rate will decrease, and vice versa). We have studied this issue in depth (8) and adapted an approach that can best evaluate the "effectiveness" of the immunoassays compared. Specifically, immunoassay and GC-MS data from a significant number of case specimens containing appropriate concentrations of the analytes of interest (and their metabolites) are first collected. Regression analyses of these data are performed to arrive at an apparent analyte concentration for each immunoassay that is equivalent to a specific analyte concentration as determined by GC-MS. Immunoassay apparent analyte concentrations thereby derived are then adapted as these immunoassays' respective cutoffs, based on which false-positive and false-negative rates are most evenly distributed. These concentrations are shown in respective plots in Figures 5 and 6 .
With this approach and adapting 500 ng/mL MDMA (or MA) as the GC-MS cutoffs, the regression analyses are illustrated in Figures 5  and 6 , and the resulting immunoassay cutoffs, and the false-positive and false-negative rates for the immunoassays examined are shown in Table VI. Among the four immunoassays shown in Table VI , the immunoassay's apparent MDMA or MA concentrations, corresponding to 500 ng/mL MDMA or MA, respectively, derived from OnLineAmp/MDMA are the highest. Thus, OnLine-Amp/MDMA generates the highest responses for both MDMA and MA, that is, detecting the presence of MDMA and MA at their lowest concentrations. (It should be noted, however, ifd-MA is used as the calibrator, CEDIA-Amp/MDMA may generate an even higher immunoassay concentration equivalent to 500 ng/mL MDMA, that is, detecting the presence of MDMA even at a lower concentrations.)
In terms of the numbers of false-negative and false-positive results generated, CEDIA-Amp/MDMA (MDMA as the calibrator for testing MDMA and d-MA as the calibrator for testing MA) appears to be the most effective immunoassay for the preliminary tests of MDMA and MA.
Conclusions
Immunoassays' performance can be characterized by examining 1. their cross-reactivities toward compounds that are related to the adapted calibrators and 2. the correlation of the resulting apparent immunoassay analyte concentrations with the analyte concentrations derived from GC-MS analysis. Prepared solutions in urine matrix are used for the former studies, whereas analyte-containing case specimens, which include normal distributions of the analytes and related metabolites, are needed (and used in this study) to derive meaningful results for the latter studies.
Among the immunoassays evaluated, many are effective for the preliminary test of MA/AM-containing specimens. CEDIAAmp/MDMA appears to be most effective in serving as the preliminary test methodology for both MDMNMDA and MA/AM (MDMA as the calibrator for testing MDMA and d-MA as the cal- Table IV , for the reason stated in the text, only 20 were adapted for regression analysis to derive the immunoassay apparent MDMA concentrations (adapted as cutoffs for respective immunoassays) that are equivalent to S00 ng/mL MDMA. However, all valid data derived from each specific immunoassay are used to derive data in this table for that specific immunoassay. Table V , for the reason stated in the text, only 24 were adapted for regression analysis to derive the immunoassay apparent MA concentrations (adapted as cutoffs for respective immunoassays) that are equivalent to 500 nglmL MA. However, all valid data derived from specific immunoassay are used to derive data in this table for that specific immunoassay.
ibrator for testing MA). CEDIA-Amp/MDMA (d-MA as the calibrator) and OnLine-Amp/MDMA can detect the presence of MDMA and MA, respectively, at the lowest concentrations.
